Recent studies have further demonstrated that targeting DHHC9 can enhance immune checkpoint blockade (ICB) immunotherapy by regulating PD‐L1 palmitoylation and indirectly modulating the tumour microenvironment [43, 44]. This evidence concerns the gene ZDHHC9 and neoplasm.